The selective BCL-2 inhibitor venetoclax has proven strong efficacy in many hematological cancers (ex., chronic lymphocytic lymphoma, acute myeloid leukemia, mantle cell lymphoma), which share its dependency on BCL-2 anti-apoptotic signaling [5,6,7]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.